FBR Capital Cuts Price Target as FuelCell Energy (FCEL) Cuts Revenue Guidance
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/14/2026
- Wall Street ends higher as SpaceX's market debut dominates
- SpaceX prices historic IPO at $135/share in largest ever new listing
- 'Ocean of opportunity': Wolfe initiates SpaceX at Buy ahead of historic IPO
- UBS cuts gold price forecasts on delayed Fed easing outlook
- Brent falls to lowest since March on expected peace deal
- NASDAQ adds five companies to NASDAQ-100 index in quarterly rebalance
- Super Micro Computer establishes $1.25 billion stock sale agreement
- Wall Street ends higher as SpaceX's market debut dominates
- 'Ocean of opportunity': Wolfe initiates SpaceX at Buy ahead of historic IPO
- SpaceX Shares Indicated To Open At $155
Notable 52-Week Highs and Lows 12/1: (GM) (MRO) (DCI) High; (EXPR) (GES) (FCEL) Low
December 1, 2016 2:20 PM EST52-Week High:General Motors (NYSE: GM) $36.66. GMs total U.S. sales in November were 252,644 vehicles, up more than 10 percent from last year. All four brands outperformed the industry in November with Buick, Cadillac and GMC posting double-digit gains. (NOTE: The Street was looking for an increase of 9.1%.)
Marathon Oil Corporation (NYSE:... More
Unusual 11 Mid-Day Movers 12/1: (HTBX) (ARDM) (EXPR) Higher; (SGY) (TLYS) (CBK) Lower
December 1, 2016 1:17 PM ESTHeat Biologics (Nasdaq: HTBX) 63.8% LOWER; announced that it presented topline data from its 94-patient Phase II trial evaluating HS-410 (vesigenurtacel-L) in combination with standard of care, Bacillus Calmette-Guérin (BCG), or as a monotherapy, for the treatment of non-muscle invasive bladder cancer. In part, the news release read: "... these responses did not translate into clinical outcomes, and there was no statistically significant difference in the primary endpoint (proportion of recurrence-free survival at one year) between the vaccine and placebo arms of the trial."
Aradigm Corporation (Nasdaq:... More
Roth Capital Affirms Rating, Price Target on FuelCell (FCEL) Amid Restructuring, Prelim. Results
December 1, 2016 10:02 AM ESTRoth Capital affirms FuelCell Energy (Nasdaq: FCEL) at Neutral with a price target of $2 following restructuring news and preannounced results.
The firm noted today:
FuelCell Energy preannounced F4Q16 (Oct.) results well below consensus. The company preannounced F4Q16 (Oct) revenue of... MorePre-Open Stock Movers 12/01: (BSTG) (BLUE) (CLC) Higher; (ARDM) (HTBX) (PTN) Lower (more...)
December 1, 2016 9:28 AM ESTToday's Pre-Open Stock Movers
Aradigm Corporation (Nasdaq: ARDM) 61.8% LOWER; announced top-line results from its two Phase 3 clinical trials (ORBIT-3 and ORBIT-4) evaluating the safety and efficacy of Pulmaquin®, the Companys investigational proprietary formulation of once daily ciprofloxacin for inhalation, in patients with non-cystic fibrosis bronchiectasis (non-CF BE) with chronic lung infections with... More
FuelCell Energy (FCEL) to Conduct Corp. Restructuring; Prelim. Q4, FY16 Revenue Light of Views
December 1, 2016 7:04 AM ESTFuelCell Energy, Inc. (Nasdaq: FCEL) announced a business restructuring to reduce costs and align production levels with current levels of demand in a manner that is consistent with the Companys long-term strategic plan.
The Company is reducing materials spend as well as implementing various cost control initiatives. The workforce was reduced at both the North American production facility in Torrington,... More
Roth Capital Halves PT on FuelCell (FCEL) to $2 Amid CT-DEEP Rejection
November 30, 2016 8:23 AM ESTRoth Capital cuts its price target on Neutral-rated FuelCell Energy (Nasdaq: FCEL) from $4 down to $2, seeing a deeper impact from CT-DEEP rejection.
The firm commented today: We are lowering our estimates and price target on rejection of FuelCell Energy's projects... More
Notable 52-Week Highs and Lows 11/29: (ARIA) (TIF) (THO) High; (NVLS) (FCEL) Low
November 29, 2016 3:43 PM EST52-Week High:ARIAD Pharmaceuticals, Inc. (Nasdaq: ARIA) $14.42. ARIAD Pharma announced that the U.S. Food and Drug Administration (FDA) has granted Iclusig (ponatinib) full approval for the treatment of adult patients with chronic phase, accelerated phase, or blast phase chronic myeloid leukemia (CML) or Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL) for whom no other tyrosine kinase inhibitor (TKI) therapy is indicated; and for the treatment of adult patients with T315I-positive CML... More
FBR Capital Cuts Price Target as FuelCell Energy (FCEL) is Shut out of Clean Energy RFP
November 29, 2016 3:05 PM ESTFBR Capital maintained a Market Perform rating on FuelCell Energy (NASDAQ: FCEL), and cut the price target to $3.00 (from $5.50), following the announced the winners of the Connecticut Department of Energy and Environmental Protection's clean energy RFP. FCEL was not among the winning bids. The company had bid multiple projects of various sizes into the RFP totaling more than 50 MW.... More
